<DOC>
	<DOCNO>NCT00598962</DOCNO>
	<brief_summary>To determine safety efficacy azithromycin , rifabutin ethambutol give three time weekly treatment lung infection M. avium complex</brief_summary>
	<brief_title>Use Azithromycin Rifabutin Administered Three Times Weekly Treatment M. Avium Complex ( MAC ) Lung Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Mycobacterium Infections</mesh_term>
	<mesh_term>Mycobacterium avium-intracellulare Infection</mesh_term>
	<mesh_term>Rifabutin</mesh_term>
	<criteria>Meet American Thoracic Society criterion nontuberculous lung disease : two AFB smear positive , culture positive sputum bronchoscopic sample and/or two AFB smear negative respiratory sample moderate heavy growth ( 2+4+ ) ; abnormal CXR consistent M. avium lung disease ; abnormal CXR consistent M. avium lung disease ; absence lung pathogen ( except coexistence M. abscessus ) . Age 18 old Pretreatment isolate M. avium complex available MIC determination Baseline laboratory clinical test baseline CBC , Chemistry ( include liver enzymes ) , hear test , visual acuity color discrimination Available long term followup History macrolide rifamycins allergy Laboratory evidence mycobacterial resistance azithromycin Children le 18 year age If menstruating female , pregnant adequate birth control HIV+ risk</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>MAC</keyword>
</DOC>